



The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Technegas® Installed at First DoD Hospital and Largest Military Medical Facility in the US

10 April, 2025 Cyclopharm Limited (ASX: CYC) today announced the **installation of Technegas® at Brooke Army Medical Center (BAMC)** in Houston, Texas. BAMC is **the first** Department of Defense (DoD) hospital to implement Cyclopharm's proprietary functional ventilation imaging agent Technegas® following the commencement of its **5-year United States Federal Supply Schedule (FSS)** contract signed on 21 March 2025.

The company also reiterated its position made on 1 April 2025 to the market, that as the US policy environment continues to evolve, Cyclopharm remains a de-risked growth opportunity in that market, with major government and private sector contracts secured and substantial inventory already onshore in the US.

BAMC, **Technegas®** latest installation site, is a joint-service facility, supporting the Army, Navy, Air Force, and Space Force. Located at Joint Base San Antonio-Fort Sam Houston, Texas, key features of BAMC include:

- The **largest military medical facility** in the United States.
- The **only Level 1 Trauma Centre** within the DoD healthcare system.
- Supports inpatient care to **active-duty service members, retirees, and their families**.
- Home to San Antonio **Uniformed Services Health Education Consortium (SAUSHEC)**, one of the largest graduate medical education platforms in the military.
- Provides telehealth and **global consultation services**, extending DoD medical expertise to deployed units worldwide.

Cyclopharm CEO James McBrayer commented "We are very proud that BAMC is the first Department of Defense hospital to implement Technegas®. BAMC is more than a hospital – it plays a critical role in the DoD healthcare system as a premier medical facility and a cornerstone of military medicine and education. This milestone serves as a strategic step in expanding the deployment of Technegas® to other Veteran Administration and DoD hospitals covered under our 5-year commercial contract with the US Federal Government."

ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director and CEO.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

For personal use only

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

Cyclopharm's Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

In the United States the Technegas approved indication for use for use is:

TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older is for the visualization of pulmonary ventilation and the evaluation of pulmonary embolism when paired with perfusion imaging.

For personal use only